anle138b

DRUG2 trials

Sponsors

MODAG GmbH

Conditions

Healthy VolunteersParkinson Disease

Phase 1

A First-in-Human Study of Single and Multiple Doses of anle138b in Healthy Subjects

CompletedNCT04208152

MODAG GmbHHealthy Volunteers

Start: 2019-12-06End: 2020-08-04Updated: 2020-08-06

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of anle138b in Parkinson's Disease

CompletedNCT04685265

MODAG GmbHParkinson Disease

Start: 2020-12-22End: 2022-12-22Updated: 2023-03-22

Related Papers

Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial.

2022-04-2961 citations